Melissa A Geller

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi request reprint Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Int J Gynecol Cancer 20:918-25. 2010
  2. doi request reprint Learning about ovarian cancer at the time of diagnosis: video versus usual care
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:370-5. 2010
  3. doi request reprint A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 118:19-23. 2010
  4. doi request reprint Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies
    Melissa A Geller
    Division of Gynecologic Oncology, University of Minnesota, Department of Obstetrics, Gynecology and Women s Health, Minneapolis, MN 55455, USA
    Eur J Obstet Gynecol Reprod Biol 143:93-7. 2009
  5. doi request reprint A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 121:112-7. 2011
  6. doi request reprint Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, MMC 395 420 Delaware St SE, Minneapolis, MN, 55455, USA
    Cancer Immunol Immunother 59:1877-84. 2010
  7. doi request reprint Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
  8. doi request reprint Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial
    Levi S Downs
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 120:265-9. 2011
  9. doi request reprint A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009
  10. ncbi request reprint A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
    Levi S Downs
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer 112:331-9. 2008

Collaborators

Detail Information

Publications24

  1. doi request reprint Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Int J Gynecol Cancer 20:918-25. 2010
    ..Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure...
  2. doi request reprint Learning about ovarian cancer at the time of diagnosis: video versus usual care
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:370-5. 2010
    ..We evaluated the effects of an educational video on patients' distress, cancer knowledge, coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis...
  3. doi request reprint A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 118:19-23. 2010
    ..We sought to evaluate the outcomes and feasibility associated with delivering sequential chemotherapy and radiation in advanced stage endometrial cancer...
  4. doi request reprint Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies
    Melissa A Geller
    Division of Gynecologic Oncology, University of Minnesota, Department of Obstetrics, Gynecology and Women s Health, Minneapolis, MN 55455, USA
    Eur J Obstet Gynecol Reprod Biol 143:93-7. 2009
    ..To evaluate the feasibility and morbidity of using saline filled tissue expanders (TE) to displace the small bowel during radiation therapy in patients with gynecologic malignancies...
  5. doi request reprint A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 121:112-7. 2011
    ..To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer...
  6. doi request reprint Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, MMC 395 420 Delaware St SE, Minneapolis, MN, 55455, USA
    Cancer Immunol Immunother 59:1877-84. 2010
    ..Secondary objectives included assessment of safety and immune system activation...
  7. doi request reprint Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
    ..We aimed to evaluate the feasibility and tolerability of hyperthermic intraperitoneal carboplatin (HIPEC-carboplatin) following secondary cytoreduction for recurrent, platinum-sensitive ovarian cancer...
  8. doi request reprint Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial
    Levi S Downs
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 120:265-9. 2011
    ....
  9. doi request reprint A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009
    ..Grade 1 toxicity included headache (1 patient) and bromidrosis (2 patients). Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common...
  10. ncbi request reprint A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
    Levi S Downs
    Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer 112:331-9. 2008
    ..Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide...
  11. ncbi request reprint Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression
    Melissa A Geller
    Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Gynecol Oncol 95:632-6. 2004
    ..With the successful application of directed biological therapy in other sarcomas, a review of the behavior and biology of this disease is warranted...
  12. ncbi request reprint Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: a retrospective analysis and literature review
    Justin C Chura
    Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Division of Gynecologic Oncology, 420 Delaware Street SE, MMC 395, Minneapolis, MN 55455, USA
    Gynecol Oncol 107:79-85. 2007
    ..Consequently, the optimal management strategy is not defined. We reviewed our institution's experience with brain metastasis from endometrial cancer along with the extant medical literature to develop management recommendations...
  13. pmc Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker
    Melissa S DeRycke
    Dept of Laboratory Medicine and Pathology, MMC 609, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    Am J Clin Pathol 134:835-45. 2010
    ....
  14. pmc A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cytotherapy 13:98-107. 2011
    ..We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer...
  15. ncbi request reprint Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer
    Patricia L Judson
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, 420 Delaware Street Southeast, MMC 395, Minneapolis, MN 55455, USA
    Gynecol Oncol 91:389-94. 2003
    ....
  16. doi request reprint Development and pilot of an advance care planning website for women with ovarian cancer: a randomized controlled trial
    Rachel Isaksson Vogel
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 131:430-6. 2013
    ..Few available tools facilitate cancer patients and physicians' discussions of quality of life and end-of-life. Our objective was to develop a web-based tool to promote advance care planning for women with ovarian cancer...
  17. doi request reprint Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA Electronic address
    Gynecol Oncol 131:368-73. 2013
    ..We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist...
  18. pmc Menopausal hormone therapy and risk of colorectal cancer
    Jill R Johnson
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
    Cancer Epidemiol Biomarkers Prev 18:196-203. 2009
    ..55; 95% CI, 0.32-0.98) had the largest risk reduction. In this study, estrogen plus progestin use, especially sequential regimen use, was associated with the largest overall reduction of colorectal cancer risk...
  19. doi request reprint Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic
    Sue V Petzel
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    J Genet Couns 22:662-73. 2013
    ..Ease of referral by the introduction of an electronic cancer genetic referral form represents another new direction that may increase genetic risk assessment for high-risk women with ovarian cancer...
  20. doi request reprint Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer
    RAHEL G GHEBRE
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55417, USA
    Gynecol Oncol 121:595-9. 2011
    ..To determine the disease characteristics and comorbidities predictive of vulvar cancer specific mortality and five year overall survival among older women, ages 65 and above...
  21. ncbi request reprint A multi-institutional review of outcomes of endometrial stromal sarcoma
    Charles A Leath
    Department of Obstetrics, Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
    Gynecol Oncol 105:630-4. 2007
    ..To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively...
  22. pmc Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients
    John D Andersen
    Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 609, 420 Delaware St, SE Minneapolis, MN, USA
    J Ovarian Res 3:21. 2010
    ..We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry...
  23. ncbi request reprint Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review
    Justin C Chura
    University of Minnesota, Department of Obstetrics, Gynecology, and Women s Health, 420 Delaware Street SE MMC 395, Minneapolis, MN 55455, USA
    Gynecol Oncol 104:247-52. 2007
    ..Studies have suggested that PET scans can differentiate between leiomyomas and leiomyosarcomas. Our experience, however, shows that PET scan-positive smooth muscle tumors are not necessarily malignant...
  24. doi request reprint Gonadal dysgenesis and gynecologic cancer
    Amy L Jonson
    Division of Gynecologic Oncology, University of Minnesota Department of Obstetrics, Gynecology, Women s Health, Minneapolis, Minnesota, USA
    Obstet Gynecol 116:550-2. 2010
    ..Gonadal dysgenesis encompasses a variety of sexual differentiation disorders. Within this population of patients, there is an increased risk of gonadal tumor formation...